Phase 2 N=22 Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
Aging · Obesity · Insulin Resistance
Primary: Change in Total Mass and Regional Adipose Adiposiy — 0.3; -1.4; -0.9; -0.7 kilograms — p=0.77
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate as Defined as the Number of Patients Who Experience a Response (Complete or Partial) to Treatment at the Time of Best Response — 12 Participants
Phase 2 N=75 Probing the Synergistic Effect of Pre-Biotics & Iron Fortificants in Anemic Subjects
Iron-deficiency
Primary: Change in Hemoglobin Concentration From Baseline to 90 Days — 11.44; 11.58; 11.54; 11.61 g/dL
Phase 2 N=65 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis
Psoriasis
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs — 0; 1; 1; 8 Participants
Phase 2 N=30 A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Phase 2 N=32 Reversal of General Anesthesia With Methylphenidate
Post Operative Cognitive Dysfunction · Emergence From Anesthesia
Primary: Number of Participants With Adverse Events — 0; 0 Participants
Phase 2 N=93 A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 48 in the PANSS Total Score — -38.5 Units on a scale
Phase 2 N=16 Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
Metastatic Soft Tissue Sarcoma
Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562
Phase 2 N=24 Trial of pIL-12/MK-3475 in Metastatic Melanoma
Melanoma
Primary: Best Overall Objective Response Rate (ORR) Within 24 Weeks Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 0.375 proportion of participants
Phase 2 N=70 Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
Bladder Cancer
Primary: Percentage of Patients Without Distant Metastases by Three Years — 77.8; 84.0 percentage of participants
Phase 2 N=54 Dose Dense MVAC for Muscle Invasive Bladder Cancer
Muscle Invasive Bladder Cancer · High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Primary: Percentage of Participants With Complete Response at Cystectomy or Ureterectomy Following Preoperative Dose Dense MVAC — 38 percentage of total participants
Phase 2 N=75 Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers
No Disease State or Condition
Primary: Stage II: Duration of Anesthesia as Measured by Pin Prick Test (PPT) for One Spray CTY-5339-A Compared to One Spray CTY-5339-CB — 14.6; 7.4 minutes
Phase 2 N=41 A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Cystic Fibrosis
Primary: Absolute Change in Total Brody/CF-CT Score — 0.90; 2.38 scores on a scale
Phase 2 N=251 A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number and Percentage of Subjects With American College of Rheumatology 20 (ACR20) at Week 12 — 45; 48; 51; 50 Participants
Phase 2 N=345 A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number and Percentage of Subjects Achieving American College of Rheumatology (ACR) 20 Response at Week 12 — 52; 57; 53; 50 Participants — p=0.172